Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection

Cost-effectiveness of rituximab strategies in rheumatoid arthritis

(2017) Raphaèle Seror et al.   LANCET

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

(2016) Duncan Porter et al.   LANCET

Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis

(2015) Markus Bredemeier et al.   CLINICAL RHEUMATOLOGY

Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial

(2013) Xavier Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Low- Versus High-Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

(2013) Markus Bredemeier et al.   ARTHRITIS CARE & RESEARCH

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

(2011) K. Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE

(2011) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) A. Rubbert-Roth et al.   RHEUMATOLOGY

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

(2009) L. Quartuccio et al.   RHEUMATOLOGY